BL LATANOPROST SOLUTION

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Aktív összetevők:

LATANOPROST

Beszerezhető a:

BAUSCH & LOMB INC

ATC-kód:

S01EE01

INN (nemzetközi neve):

LATANOPROST

Adagolás:

50MCG

Gyógyszerészeti forma:

SOLUTION

Összetétel:

LATANOPROST 50MCG

Az alkalmazás módja:

OPHTHALMIC

db csomag:

2.5ML

Recept típusa:

Prescription

Terápiás terület:

PROSTAGLANDIN ANALOGS

Termék összefoglaló:

Active ingredient group (AIG) number: 0132916002; AHFS:

Engedélyezési státusz:

APPROVED

Engedély dátuma:

2013-04-02

Termékjellemzők

PRODUCT MONOGRAPH
PR
BL LATANOPROST
Latanoprost Ophthalmic Solution
50 mcg/mL
PROSTAGLANDIN F2Α ANALOGUE
BAUSCH & LOMB INCORPORATED DATE OF REVISION:
1400 North Goodman Street
June 30, 2022
Rochester NY, USA
14609
Imported and Distributed by:
BAUSCH + LOMB CORPORATION
520 Applewood Crescent
Vaughan, Ontario
L4K 4B4
Control #: 260462
_Pr_
_BL LATANOPROST Product Monograph _
_Page 2 of 28_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY
PRODUCT
INFORMATION..............................................................................
3
INDICATIONS
AND
CLINICAL
USE
...................................................................................
3
CONTRAINDICATIONS.......................................................................................................
3
WARNINGS
AND
PRECAUTIONS
......................................................................................
4
ADVERSE
REACTIONS
.......................................................................................................
6
DRUG
INTERACTIONS
.......................................................................................................
7
DOSAGE
AND
ADMINISTRATION
.....................................................................................
7
OVERDOSAGE.....................................................................................................................
8
ACTION
AND
CLINICAL
PHARMACOLOGY
.................................................................... 9
STORAGE
AND
STABILITY
...............................................................................................10
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING .....................................................10
PART II: SCIENTIFIC INFORMATION
.............................................................................
11
PHARMACEUTICAL
INFORMATION................................................................................11
CLINICAL
TRIALS
.........................